Praxis Precision Medicine is a clinical-stage biotech with analysts collectively seeing 137% upside to a price target of $564.83, but the stock is burning cash, scores 1.6 out of 10 on business quality, has an oversold RSI of 28, and carries an elevated put-to-call ratio of 2.69, making it a high-risk binary outcome driven by clinical trial results.
Thesis pillars
- Cash Burn No Revenue→Stable
- Analyst Upside Potential Catalyst↓Deteriorating
- Oversold Rsi Momentum Weakness↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026
Praxis Precision Medicines, Inc (PRAX) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $285.48: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend.
Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company with four product candidates targeting epilepsy and movement disorders via two platforms: Cerebrum (small molecule) and Solidus (ASO). NDAs are pending FDA review for ulixacaltamide (essential tremor)... Read more
Sell if holding. Engine safety override at $285.48: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Praxis Precision Medicines, Inc
About Praxis Precision Medicines, Inc
Praxis Precision Medicines submitted two NDAs to the FDA in 2025 — ulixacaltamide for essential tremor (Essential3 Phase 3 met primary and all key secondary endpoints) and relutrigine for SCN2A-DEE and SCN8A-DEE (EMBOLD Phase 2 study stopped early for efficacy, with a 53% placebo-adjusted seizure reduction). Net losses were $303.3 million in 2025 versus $182.8 million in 2024, with an accumulated deficit of $1.1 billion at December 31, 2025. Cash, equivalents, and marketable securities are estimated sufficient to fund operations into 2028.
Praxis generates no commercial revenue. The Cerebrum small molecule platform yielded three clinical-stage candidates: ulixacaltamide (a T-type calcium channel inhibitor for essential tremor, with FDA Breakthrough Therapy Designation granted), vormatrigine (a NaV channel modulator for focal onset seizures with POWER1 Phase 2/3 topline results expected Q2 2026 and POWER2 Phase 3 enrolling), and relutrigine (persistent sodium current inhibitor for DEEs with a 53% placebo-adjusted seizure reduction in EMBOLD). The Solidus ASO platform generated elsunersen for early-onset SCN2A-DEE, plus three preclinical candidates targeting PCDH19, SYNGAP1, and SCN2A loss-of-function mutations. The company relies on third-party CROs for clinical execution globally and has not publicly announced commercial-scale manufacturing contracts. If ulixacaltamide receives FDA approval, the company plans to commercialize independently in the U.S., while Tenacia Biotechnology (Shanghai) holds exclusive rights to develop and commercialize ulixacaltamide in China, Hong Kong, Macau, and Taiwan under a collaboration and license agreement.
Show full overview
Both pending FDA NDA decisions carry binary risk. The ulixacaltamide NDA rests on Essential3 data where Study 1 met its primary endpoint and all key secondary endpoints, and Study 2 met its primary endpoint; an FDA Complete Response Letter could require additional clinical work. The relutrigine NDA is supported by Phase 2 EMBOLD data stopped early for efficacy; if approved, a supplemental NDA for broader DEEs is planned for 2027 contingent on positive EMERALD Phase 3 results, with full enrollment expected in the second half of 2026. A denial or delay for either NDA would materially extend the timeline to first commercial revenue.
See also: Healthcare · Biotechnology
From Praxis Precision Medicines, Inc's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-10-29Recent Developments — Praxis Precision Medicines, Inc
Latest news
- NEWS Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Par — fiscal.ai Oct 27, 2026 neutral
- NEWS Lennox-Gastaut Syndrome (LGS) Foundation Announces 2026 International LGS Awareness Day Partners — fiscal.ai Oct 22, 2026 neutral
- NEWS JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700 — benzinga Oct 16, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target — benzinga Oct 15, 2026 positive
- NEWS BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826 — benzinga Oct 6, 2026 positive
Generated 2026-10-29T11:14:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineulixacaltamide10-K Item 1: 'Our most advanced program, ulixacaltamide, is a differentiated and highly selective small molecule inhibitor of T-type calcium channels in development for the treatment of essential tremor'
- MEDIUMpipelinerelutrigine10-K Item 1: 'We have submitted an NDA for relutrigine for the treatment of SCN2A-DEE and SCN8A-DEE to the FDA based on data from the EMBOLD study'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $285.48: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $265.50. Score 5.7/10, moderate confidence.
Analyst target: $585.00 (+104.9% upside). Prior stop was $265.50. Stop-loss: $265.50.
Quality below floor (1.6 < 4.0).
Praxis Precision Medicines, Inc trades at a P/E of N/A (forward -30.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
25 analysts cover PRAX with a consensus score of 4.2/5. Average price target: $650.
What does Praxis Precision Medicines, Inc do?Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company with four product candidates targeting...
Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company with four product candidates targeting epilepsy and movement disorders via two platforms: Cerebrum (small molecule) and Solidus (ASO). NDAs are pending FDA review for ulixacaltamide (essential tremor) and relutrigine (SCN2A-DEE and SCN8A-DEE); vormatrigine and elsunersen are in earlier clinical stages. The company reported a net loss of $303.3 million in 2025 and had no commercial revenue at year-end.